Oppenheimer downgraded Emerson (NYSE: EMR) from Outperform to Perform, citing a lack of high conviction catalysts to drive multiple expansion ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE